A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer

Goksel, TUNCAY; HATİPOĞLU, OSMAN; ÖZTÜRK, CAN; Gorguner, M; Kiyik, M; YILMAZ, UĞUR; GÜZELANT, ASUMAN; Tasbakan, S; TABAKOĞLU, ERHAN; FIRAT, HİKMET; TUTAR, ÜMİT; Cikrikicioglu, S; AKKOÇLU, ATİLA; Soyer, SERDAR; Cakir, ENGİN; Itil, O; SANAL, SALAHATTİN

doi:10.1111/j.1440-1843.2005.00739.x

A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer

Atıf İçin Kopyala

Goksel T. , HATİPOĞLU O. N. , ÖZTÜRK C., Gorguner M., Kiyik M., YILMAZ U. E. , ...Daha Fazla

RESPIROLOGY, cilt.10, ss.456-463, 2005 (SCI İndekslerine Giren Dergi)

Cilt numarası: 10 Konu: 4
Basım Tarihi: 2005
Doi Numarası: 10.1111/j.1440-1843.2005.00739.x
Dergi Adı: RESPIROLOGY
Sayfa Sayıları: ss.456-463

Özet

Cisplatin-gemcitabine (PG) and cisplatin-etoposide (PE) combinations are active regimens for non-small cell lung cancer (NSCLC). The present study aimed to compare PG with PE in the treatment of patients with stage IIIB and IV NSCLC.